We have a broad portfolio covering a wide range of therapeutic areas, and across modalities, from small molecules to cell therapy. Many have already attracted investments from top tier investors such as BB Pureos Bioventures, NEA, Syncona, Sofinnova, the Novartis Venture Fund, Biomedinvest, Boehringer Ingelheim Venture Fund, Kurma Partners, Sunstone Life Science Ventures, Ysios Capital,  Morningside Venture Investments, Jeito Capital and others.

Financed: $80M raised

New target/core pathway for fibrosis. Treatment of late-stage fibrosis, related cancers. Initially liver.

Financed: $37.5M raised

Antibody platform re-focusing IL-2 to CTLs to fuel anti-cancer immunity.


First-in-class therapeutics to stop neurodegenerative diseases with a selective small molecule approach.


Tag cell populations for removal or shielding. Better, safer safe bone marrow transplants and stem cell replacement.


Developing novel inflammasome inhibitors.


 Highly potent and specific therapies based on T cell receptor (TCR), targeting of solid tumors.


Platform to create compartment locked biologics for higher local retention and fast systemic degradation


A novel class of immunosuppressive therapies for autoimmune inflammatory diseases and organ transplantation


Gene logic circuits. In-vivo multifactorial identification and killing of cancer cells.


Bacterial mixes as microbiome therapeutics in IBD and oncology based on mixed-culture technology.

Financed: $41.5M raised

Glycomimetic platform for removing auto-antibodies in autoimmune neuropathies.

Financed: $25M raised

Novel targets that mediate endocannabinoid efficacy. Treatments for stress, anxiety etc.

Financed: $42M raised

Intracellular delivery of therapeutic payloads using bacteria, exploiting bacterial tumor targeting.


Functional ID of (neo)antigens for cancer, immunological and infectious diseases.

Financed: $16.5M raised

Cancer drug resistance platform to develop small molecules addressing non mutational mechanisms of therapy evasion.

Financed: $18.5M raised

mRNA platform for local regenerative medicine-based therapeutics.

Application cycle is now open!

The next deadline for 2021 is December 19.